• 1. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

6-Bromo-3-cyclopropyl-1-methylindazole (CAS No. 1311197-86-0): A Comprehensive Overview

6-Bromo-3-cyclopropyl-1-methylindazole (CAS No. 1311197-86-0) is a specialized heterocyclic compound that has garnered significant attention in pharmaceutical and agrochemical research. This brominated indazole derivative features a unique molecular structure combining a cyclopropyl group and methyl substitution, making it particularly valuable for drug discovery applications. Researchers are increasingly interested in this compound due to its potential as a kinase inhibitor scaffold and its relevance to cancer research.

The compound's molecular formula (C₁₁H₁₁BrN₂) and molecular weight of 251.12 g/mol position it as an important intermediate in medicinal chemistry. Its structural features - particularly the 6-bromo substitution pattern on the indazole core - make it highly versatile for further functionalization through cross-coupling reactions. Many scientists searching for "indazole derivatives for drug development" or "brominated heterocycles in pharmaceuticals" will find this compound particularly relevant to their work.

Recent studies have highlighted the importance of 6-Bromo-3-cyclopropyl-1-methylindazole in developing targeted therapies, especially in the context of personalized medicine approaches. The compound's ability to serve as a building block for kinase inhibitors aligns with current trends in precision oncology, where researchers are actively seeking novel scaffolds with improved selectivity profiles. This connection to cancer drug discovery makes it a hot topic in scientific literature and patent applications.

From a synthetic chemistry perspective, the cyclopropyl group in 6-Bromo-3-cyclopropyl-1-methylindazole offers interesting possibilities for conformational restriction of potential drug candidates. This feature is particularly valuable when designing compounds with enhanced target binding affinity and metabolic stability. Many medicinal chemists searching for "constrained indazole derivatives" or "cyclopropyl-containing bioactive molecules" frequently encounter this compound in their research.

The commercial availability of 6-Bromo-3-cyclopropyl-1-methylindazole has increased significantly in recent years, reflecting growing demand from both academic and industrial research sectors. Suppliers typically offer this compound with high purity (>95%) for research purposes, though specific handling and storage conditions should always be followed. Researchers interested in "purchasing 6-Bromo-3-cyclopropyl-1-methylindazole" or "CAS 1311197-86-0 suppliers" can find multiple sourcing options through specialized chemical distributors.

In the context of intellectual property, 6-Bromo-3-cyclopropyl-1-methylindazole appears in several patent applications related to kinase modulation and inflammatory disease treatments. Its structural features make it particularly valuable for creating selective JAK inhibitors and other signal transduction modulators. This connection to drug discovery patents makes it an important compound for pharmaceutical companies developing new therapeutic agents.

Analytical characterization of 6-Bromo-3-cyclopropyl-1-methylindazole typically involves standard techniques including HPLC purity analysis, mass spectrometry, and NMR spectroscopy. The compound's distinct spectral features (particularly the characteristic signals from the cyclopropyl protons and aromatic bromine) make it relatively straightforward to identify and characterize. These analytical aspects are important for researchers searching for "NMR data for brominated indazoles" or "HPLC methods for heterocyclic compounds".

Looking toward future applications, 6-Bromo-3-cyclopropyl-1-methylindazole continues to show promise in multiple areas of medicinal chemistry research. Its versatility as a synthetic intermediate, combined with its interesting pharmacophore potential, ensures it will remain relevant in drug discovery programs. The compound's unique combination of a bromine handle for further derivatization and a constrained cyclopropyl group offers medicinal chemists valuable opportunities for structure-activity relationship studies.

For researchers working in fragment-based drug discovery, 6-Bromo-3-cyclopropyl-1-methylindazole represents an attractive starting point due to its moderate molecular weight and good ligand efficiency potential. The compound's drug-like properties make it suitable for screening in various biological assays, particularly those targeting kinase enzymes. This aligns well with current trends in hit-to-lead optimization strategies, where researchers seek structurally diverse fragments with clear growth vectors.

In summary, 6-Bromo-3-cyclopropyl-1-methylindazole (CAS No. 1311197-86-0) stands as an important building block in modern pharmaceutical research and medicinal chemistry. Its unique structural features, synthetic versatility, and relevance to current drug discovery trends ensure its continued importance in scientific research. As the field moves toward more targeted therapeutic approaches, compounds like this will play increasingly vital roles in developing the next generation of bioactive molecules.

• 215815-10-4(1-Benzyl-3-ethyl-6-bromo-1H-indazole)
• 865156-32-7(1H-INDAZOLE, 5-BROMO-3-(3-METHOXYPROPYL)-1-METHYL-)
• 98295-51-3(1H-Indazole, 6-bromo-1-methyl-3-(4-piperidinyl)-)
• 1311197-90-6(6-Bromo-3-cyclopropyl-1H-indazole)
• 1276075-34-3(6-Bromo-3-ethyl-1-isopropyl-1h-indazole)
• 911305-80-1(5-Bromo-3-cyclopropyl-1H-indazole)
• 1095539-84-6(6-Bromo-1,3-dimethyl-1H-indazole)
• 215815-09-1(6-bromo-3-ethyl-1-methylindazole)
• 64635-14-9(1H-BENZ[F]INDAZOLE, 3-(1,1-DIMETHYLETHYL)-1-METHYL-)
• 1311197-79-1(5-Bromo-3-cyclopropyl-1-methylindazole)